The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global VRE and MRSA Antibiotic Market Outlook 2024
Synopsis
Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) are specific, antibiotic-resistant bacteria that spread by contact and can cause serious infections. MRSA can be spread by touching articles that have been contaminated by the skin of an infected or colonized person, such as towels, sheets, and wound dressings; VRE can be transmitted by touching articles soiled by an infected person’s feces. Both of these bacteria survive well on hands and for weeks on inanimate objects. Colonization occurs when bacteria are present on or in the body (i.e., nose, skin, rectum, moist areas of the body and the newborn’s umbilicus) without causing illness.
An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections. They may either kill or inhibit the growth of bacteria.
The market for is VRE and MRSA Antibiotic market fragmented with players such as Pfizer, Lilly, Sanofi Aventis, Merck, Fresenius Kabi, Xellia Pharmaceuticals (Novo Holdings), Zhejiang Medicine, Zhejiang Hisun Pharmaceutical, North China Pharmaceutical. Among the companies, pfizer contributed 16% of the market, which is the biggest in 2019.
Category, included in this market are Teicoplanin, Vancomycin, Linezolid, Daptomycin, Others. The Linezolid contributed most in the revenue of the VRE and MRSA Antibiotic，which is 38% of the market.
The application for VRE and MRSA Antibiotic market is segment with application such as hospitals, clinics and others, in 2020, the sales in the hospitals is the biggest, occupies almost 2/3 of the market.
As for the regional market share, the Americas is expected to hold the largest share of the global MRSA drugs market.
The global VRE and MRSA Antibiotic market was valued at US$ 3886.2 million in 2020 and is expected to reach US$ 5369 million by the end of 2027, growing at a CAGR of 4.7% during 2021-2027.
This report focuses on VRE and MRSA Antibiotic volume and value at the global level, regional level and company level. From a global perspective, this report represents overall VRE and MRSA Antibiotic market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global VRE and MRSA Antibiotic Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Vancomycin
Teicoplanin
Linezolid
Daptomycin
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Pfizer
Lilly
Sanofi Aventis
Merck
Fresenius Kabi
Xellia Pharmaceuticals (Novo Holdings)
Zhejiang Medicine
Zhejiang Hisun Pharmaceutical
North China Pharmaceutical
Korea United Pharm
Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) are specific, antibiotic-resistant bacteria that spread by contact and can cause serious infections. MRSA can be spread by touching articles that have been contaminated by the skin of an infected or colonized person, such as towels, sheets, and wound dressings; VRE can be transmitted by touching articles soiled by an infected person’s feces. Both of these bacteria survive well on hands and for weeks on inanimate objects. Colonization occurs when bacteria are present on or in the body (i.e., nose, skin, rectum, moist areas of the body and the newborn’s umbilicus) without causing illness.
An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections. They may either kill or inhibit the growth of bacteria.
The market for is VRE and MRSA Antibiotic market fragmented with players such as Pfizer, Lilly, Sanofi Aventis, Merck, Fresenius Kabi, Xellia Pharmaceuticals (Novo Holdings), Zhejiang Medicine, Zhejiang Hisun Pharmaceutical, North China Pharmaceutical. Among the companies, pfizer contributed 16% of the market, which is the biggest in 2019.
Category, included in this market are Teicoplanin, Vancomycin, Linezolid, Daptomycin, Others. The Linezolid contributed most in the revenue of the VRE and MRSA Antibiotic，which is 38% of the market.
The application for VRE and MRSA Antibiotic market is segment with application such as hospitals, clinics and others, in 2020, the sales in the hospitals is the biggest, occupies almost 2/3 of the market.
As for the regional market share, the Americas is expected to hold the largest share of the global MRSA drugs market.
The global VRE and MRSA Antibiotic market was valued at US$ 3886.2 million in 2020 and is expected to reach US$ 5369 million by the end of 2027, growing at a CAGR of 4.7% during 2021-2027.
This report focuses on VRE and MRSA Antibiotic volume and value at the global level, regional level and company level. From a global perspective, this report represents overall VRE and MRSA Antibiotic market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global VRE and MRSA Antibiotic Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Vancomycin
Teicoplanin
Linezolid
Daptomycin
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Pfizer
Lilly
Sanofi Aventis
Merck
Fresenius Kabi
Xellia Pharmaceuticals (Novo Holdings)
Zhejiang Medicine
Zhejiang Hisun Pharmaceutical
North China Pharmaceutical
Korea United Pharm
Index1 VRE and MRSA Antibiotic Market Overview
1.1 Product Overview and Scope of VRE and MRSA Antibiotic
1.2 VRE and MRSA Antibiotic Segment by Type
1.2.1 Global VRE and MRSA Antibiotic Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Vancomycin
1.2.3 Teicoplanin
1.2.4 Linezolid
1.2.5 Daptomycin
1.2.6 Others
1.3 VRE and MRSA Antibiotic Segment by Application
1.3.1 Global VRE and MRSA Antibiotic Sales Comparison by Application: (2021-2027)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global VRE and MRSA Antibiotic Market Size Estimates and Forecasts
1.4.1 Global VRE and MRSA Antibiotic Revenue 2016-2027
1.4.2 Global VRE and MRSA Antibiotic Sales 2016-2027
1.4.3 VRE and MRSA Antibiotic Market Size by Region: 2016 Versus 2021 Versus 2027
2 VRE and MRSA Antibiotic Market Competition by Manufacturers
2.1 Global VRE and MRSA Antibiotic Sales Market Share by Manufacturers (2016-2021)
2.2 Global VRE and MRSA Antibiotic Revenue Market Share by Manufacturers (2016-2021)
2.3 Global VRE and MRSA Antibiotic Average Price by Manufacturers (2016-2021)
2.4 Manufacturers VRE and MRSA Antibiotic Manufacturing Sites, Area Served, Product Type
2.5 VRE and MRSA Antibiotic Market Competitive Situation and Trends
2.5.1 VRE and MRSA Antibiotic Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest VRE and MRSA Antibiotic Players Market Share by Revenue
2.5.3 Global VRE and MRSA Antibiotic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 VRE and MRSA Antibiotic Retrospective Market Scenario by Region
3.1 Global VRE and MRSA Antibiotic Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global VRE and MRSA Antibiotic Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America VRE and MRSA Antibiotic Market Facts & Figures by Country
3.3.1 North America VRE and MRSA Antibiotic Sales by Country
3.3.2 North America VRE and MRSA Antibiotic Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe VRE and MRSA Antibiotic Market Facts & Figures by Country
3.4.1 Europe VRE and MRSA Antibiotic Sales by Country
3.4.2 Europe VRE and MRSA Antibiotic Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific VRE and MRSA Antibiotic Market Facts & Figures by Region
3.5.1 Asia Pacific VRE and MRSA Antibiotic Sales by Region
3.5.2 Asia Pacific VRE and MRSA Antibiotic Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America VRE and MRSA Antibiotic Market Facts & Figures by Country
3.6.1 Latin America VRE and MRSA Antibiotic Sales by Country
3.6.2 Latin America VRE and MRSA Antibiotic Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa VRE and MRSA Antibiotic Market Facts & Figures by Country
3.7.1 Middle East and Africa VRE and MRSA Antibiotic Sales by Country
3.7.2 Middle East and Africa VRE and MRSA Antibiotic Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global VRE and MRSA Antibiotic Historic Market Analysis by Type
4.1 Global VRE and MRSA Antibiotic Sales Market Share by Type (2016-2021)
4.2 Global VRE and MRSA Antibiotic Revenue Market Share by Type (2016-2021)
4.3 Global VRE and MRSA Antibiotic Price by Type (2016-2021)
5 Global VRE and MRSA Antibiotic Historic Market Analysis by Application
5.1 Global VRE and MRSA Antibiotic Sales Market Share by Application (2016-2021)
5.2 Global VRE and MRSA Antibiotic Revenue Market Share by Application (2016-2021)
5.3 Global VRE and MRSA Antibiotic Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Pfizer VRE and MRSA Antibiotic Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Lilly
6.2.1 Lilly Corporation Information
6.2.2 Lilly Description and Business Overview
6.2.3 Lilly VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Lilly VRE and MRSA Antibiotic Product Portfolio
6.2.5 Lilly Recent Developments/Updates
6.3 Sanofi Aventis
6.3.1 Sanofi Aventis Corporation Information
6.3.2 Sanofi Aventis Description and Business Overview
6.3.3 Sanofi Aventis VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Sanofi Aventis VRE and MRSA Antibiotic Product Portfolio
6.3.5 Sanofi Aventis Recent Developments/Updates
6.4 Merck
6.4.1 Merck Corporation Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Merck VRE and MRSA Antibiotic Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 Fresenius Kabi
6.5.1 Fresenius Kabi Corporation Information
6.5.2 Fresenius Kabi Description and Business Overview
6.5.3 Fresenius Kabi VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Fresenius Kabi VRE and MRSA Antibiotic Product Portfolio
6.5.5 Fresenius Kabi Recent Developments/Updates
6.6 Xellia Pharmaceuticals (Novo Holdings)
6.6.1 Xellia Pharmaceuticals (Novo Holdings) Corporation Information
6.6.2 Xellia Pharmaceuticals (Novo Holdings) Description and Business Overview
6.6.3 Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Product Portfolio
6.6.5 Xellia Pharmaceuticals (Novo Holdings) Recent Developments/Updates
6.7 Zhejiang Medicine
6.6.1 Zhejiang Medicine Corporation Information
6.6.2 Zhejiang Medicine Description and Business Overview
6.6.3 Zhejiang Medicine VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Zhejiang Medicine VRE and MRSA Antibiotic Product Portfolio
6.7.5 Zhejiang Medicine Recent Developments/Updates
6.8 Zhejiang Hisun Pharmaceutical
6.8.1 Zhejiang Hisun Pharmaceutical Corporation Information
6.8.2 Zhejiang Hisun Pharmaceutical Description and Business Overview
6.8.3 Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Product Portfolio
6.8.5 Zhejiang Hisun Pharmaceutical Recent Developments/Updates
6.9 North China Pharmaceutical
6.9.1 North China Pharmaceutical Corporation Information
6.9.2 North China Pharmaceutical Description and Business Overview
6.9.3 North China Pharmaceutical VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2016-2021)
6.9.4 North China Pharmaceutical VRE and MRSA Antibiotic Product Portfolio
6.9.5 North China Pharmaceutical Recent Developments/Updates
6.10 Korea United Pharm
6.10.1 Korea United Pharm Corporation Information
6.10.2 Korea United Pharm Description and Business Overview
6.10.3 Korea United Pharm VRE and MRSA Antibiotic Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Korea United Pharm VRE and MRSA Antibiotic Product Portfolio
6.10.5 Korea United Pharm Recent Developments/Updates
7 VRE and MRSA Antibiotic Manufacturing Cost Analysis
7.1 VRE and MRSA Antibiotic Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of VRE and MRSA Antibiotic
7.4 VRE and MRSA Antibiotic Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 VRE and MRSA Antibiotic Distributors List
8.3 VRE and MRSA Antibiotic Customers
9 VRE and MRSA Antibiotic Market Dynamics
9.1 VRE and MRSA Antibiotic Industry Trends
9.2 VRE and MRSA Antibiotic Growth Drivers
9.3 VRE and MRSA Antibiotic Market Challenges
9.4 VRE and MRSA Antibiotic Market Restraints
10 Global Market Forecast
10.1 VRE and MRSA Antibiotic Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of VRE and MRSA Antibiotic by Type (2022-2027)
10.1.2 Global Forecasted Revenue of VRE and MRSA Antibiotic by Type (2022-2027)
10.2 VRE and MRSA Antibiotic Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of VRE and MRSA Antibiotic by Application (2022-2027)
10.2.2 Global Forecasted Revenue of VRE and MRSA Antibiotic by Application (2022-2027)
10.3 VRE and MRSA Antibiotic Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of VRE and MRSA Antibiotic by Region (2022-2027)
10.3.2 Global Forecasted Revenue of VRE and MRSA Antibiotic by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesList of Tables
Table 1. Global VRE and MRSA Antibiotic Sales (M Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global VRE and MRSA Antibiotic Sales (M Units) Comparison by Application (2021-2027)
Table 3. Global VRE and MRSA Antibiotic Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers VRE and MRSA Antibiotic Covered in This Study
Table 5. Global VRE and MRSA Antibiotic Sales (M Units) of Key Manufacturers (2016-2021)
Table 6. Global VRE and MRSA Antibiotic Sales Market Share by Manufacturers (2016-2021)
Table 7. Global VRE and MRSA Antibiotic Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global VRE and MRSA Antibiotic Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market VRE and MRSA Antibiotic Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers VRE and MRSA Antibiotic Manufacturing Sites and Area Served
Table 11. Manufacturers VRE and MRSA Antibiotic Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global VRE and MRSA Antibiotic by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in VRE and MRSA Antibiotic as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global VRE and MRSA Antibiotic Sales by Region (2016-2021) & (M Units)
Table 16. Global VRE and MRSA Antibiotic Sales Market Share by Region (2016-2021)
Table 17. Global VRE and MRSA Antibiotic Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America VRE and MRSA Antibiotic Sales by Country (2016-2021) & (M Units)
Table 19. North America VRE and MRSA Antibiotic Sales Market Share by Country (2016-2021)
Table 20. North America VRE and MRSA Antibiotic Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America VRE and MRSA Antibiotic Revenue Market Share by Country (2016-2021)
Table 22. Europe VRE and MRSA Antibiotic Sales by Country (2016-2021) & (M Units)
Table 23. Europe VRE and MRSA Antibiotic Sales Market Share by Country (2016-2021)
Table 24. Europe VRE and MRSA Antibiotic Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe VRE and MRSA Antibiotic Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific VRE and MRSA Antibiotic Sales by Region (2016-2021) & (M Units)
Table 27. Asia Pacific VRE and MRSA Antibiotic Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific VRE and MRSA Antibiotic Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific VRE and MRSA Antibiotic Revenue Market Share by Region (2016-2021)
Table 30. Latin America VRE and MRSA Antibiotic Sales by Country (2016-2021) & (M Units)
Table 31. Latin America VRE and MRSA Antibiotic Sales Market Share by Country (2016-2021)
Table 32. Latin America VRE and MRSA Antibiotic Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America VRE and MRSA Antibiotic Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa VRE and MRSA Antibiotic Sales by Country (2016-2021) & (M Units)
Table 35. Middle East and Africa VRE and MRSA Antibiotic Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa VRE and MRSA Antibiotic Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa VRE and MRSA Antibiotic Revenue Market Share by Country (2016-2021)
Table 38. Global VRE and MRSA Antibiotic Sales (M Units) by Type (2016-2021)
Table 39. Global VRE and MRSA Antibiotic Sales Market Share by Type (2016-2021)
Table 40. Global VRE and MRSA Antibiotic Revenue (Million US$) by Type (2016-2021)
Table 41. Global VRE and MRSA Antibiotic Revenue Share by Type (2016-2021)
Table 42. Global VRE and MRSA Antibiotic Price (USD/Unit) by Type (2016-2021)
Table 43. Global VRE and MRSA Antibiotic Sales (M Units) by Application (2016-2021)
Table 44. Global VRE and MRSA Antibiotic Sales Market Share by Application (2016-2021)
Table 45. Global VRE and MRSA Antibiotic Revenue (Million US$) by Application (2016-2021)
Table 46. Global VRE and MRSA Antibiotic Revenue Share by Application (2016-2021)
Table 47. Global VRE and MRSA Antibiotic Price (USD/Unit) by Application (2016-2021)
Table 48. Pfizer Corporation Information
Table 49. Pfizer Description and Business Overview
Table 50. Pfizer VRE and MRSA Antibiotic Sales (M Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. Pfizer VRE and MRSA Antibiotic Product
Table 52. Pfizer Recent Developments/Updates
Table 53. Lilly Corporation Information
Table 54. Lilly Description and Business Overview
Table 55. Lilly VRE and MRSA Antibiotic Sales (M Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. Lilly VRE and MRSA Antibiotic Product
Table 57. Lilly Recent Developments/Updates
Table 58. Sanofi Aventis Corporation Information
Table 59. Sanofi Aventis Description and Business Overview
Table 60. Sanofi Aventis VRE and MRSA Antibiotic Sales (M Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. Sanofi Aventis VRE and MRSA Antibiotic Product
Table 62. Sanofi Aventis Recent Developments/Updates
Table 63. Merck Corporation Information
Table 64. Merck Description and Business Overview
Table 65. Merck VRE and MRSA Antibiotic Sales (M Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. Merck VRE and MRSA Antibiotic Product
Table 67. Merck Recent Developments/Updates
Table 68. Fresenius Kabi Corporation Information
Table 69. Fresenius Kabi Description and Business Overview
Table 70. Fresenius Kabi VRE and MRSA Antibiotic Sales (M Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Fresenius Kabi VRE and MRSA Antibiotic Product
Table 72. Fresenius Kabi Recent Developments/Updates
Table 73. Xellia Pharmaceuticals (Novo Holdings) Corporation Information
Table 74. Xellia Pharmaceuticals (Novo Holdings) Description and Business Overview
Table 75. Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Sales (M Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 76. Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Product
Table 77. Xellia Pharmaceuticals (Novo Holdings) Recent Developments/Updates
Table 78. Zhejiang Medicine Corporation Information
Table 79. Zhejiang Medicine Description and Business Overview
Table 80. Zhejiang Medicine VRE and MRSA Antibiotic Sales (M Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 81. Zhejiang Medicine VRE and MRSA Antibiotic Product
Table 82. Zhejiang Medicine Recent Developments/Updates
Table 83. Zhejiang Hisun Pharmaceutical Corporation Information
Table 84. Zhejiang Hisun Pharmaceutical Description and Business Overview
Table 85. Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Sales (M Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 86. Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Product
Table 87. Zhejiang Hisun Pharmaceutical Recent Developments/Updates
Table 88. North China Pharmaceutical Corporation Information
Table 89. North China Pharmaceutical Description and Business Overview
Table 90. North China Pharmaceutical VRE and MRSA Antibiotic Sales (M Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 91. North China Pharmaceutical VRE and MRSA Antibiotic Product
Table 92. North China Pharmaceutical Recent Developments/Updates
Table 93. Korea United Pharm Corporation Information
Table 94. Korea United Pharm Description and Business Overview
Table 95. Korea United Pharm VRE and MRSA Antibiotic Sales (M Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 96. Korea United Pharm VRE and MRSA Antibiotic Product
Table 97. Korea United Pharm Recent Developments/Updates
Table 98. Production Base and Market Concentration Rate of Raw Material
Table 99. Key Suppliers of Raw Materials
Table 100. VRE and MRSA Antibiotic Distributors List
Table 101. VRE and MRSA Antibiotic Customers List
Table 102. VRE and MRSA Antibiotic Market Trends
Table 103. VRE and MRSA Antibiotic Growth Drivers
Table 104. VRE and MRSA Antibiotic Market Challenges
Table 105. VRE and MRSA Antibiotic Market Restraints
Table 106. Global VRE and MRSA Antibiotic Sales Forecast by Type (2022-2027) & (M Units)
Table 107. Global VRE and MRSA Antibiotic Sales Market Share Forecast by Type (2022-2027)
Table 108. Global VRE and MRSA Antibiotic Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 109. Global VRE and MRSA Antibiotic Revenue Market Share Forecast by Type (2022-2027)
Table 110. Global VRE and MRSA Antibiotic Sales Forecast by Application (2022-2027) & (M Units)
Table 111. Global VRE and MRSA Antibiotic Sales Market Share Forecast by Application (2022-2027)
Table 112. Global VRE and MRSA Antibiotic Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 113. Global VRE and MRSA Antibiotic Revenue Market Share Forecast by Application (2022-2027)
Table 114. Global VRE and MRSA Antibiotic Sales Forecast by Region (2022-2027) & (M Units)
Table 115. Global VRE and MRSA Antibiotic Sales Market Share Forecast by Region (2022-2027)
Table 116. Global VRE and MRSA Antibiotic Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 117. Global VRE and MRSA Antibiotic Revenue Market Share Forecast by Region (2022-2027)
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of VRE and MRSA Antibiotic
Figure 2. Global VRE and MRSA Antibiotic Market Share by Type in 2020 & 2027
Figure 3. Vancomycin Product Picture
Figure 4. Teicoplanin Product Picture
Figure 5. Linezolid Product Picture
Figure 6. Daptomycin Product Picture
Figure 7. Others Product Picture
Figure 8. Global VRE and MRSA Antibiotic Market Share by Application in 2020 & 2027
Figure 9. Hospitals
Figure 10. Clinics
Figure 11. Others
Figure 12. Global VRE and MRSA Antibiotic Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global VRE and MRSA Antibiotic Market Size 2016-2027 (US$ Million)
Figure 14. Global VRE and MRSA Antibiotic Sales 2016-2027 (M Units)
Figure 15. Global VRE and MRSA Antibiotic Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 16. VRE and MRSA Antibiotic Sales Share by Manufacturers in 2020
Figure 17. Global VRE and MRSA Antibiotic Revenue Share by Manufacturers in 2020
Figure 18. The Global 5 and 10 Largest VRE and MRSA Antibiotic Players: Market Share by Revenue in 2020
Figure 19. VRE and MRSA Antibiotic Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 20. Global VRE and MRSA Antibiotic Sales Market Share by Region (2016-2021)
Figure 21. Global VRE and MRSA Antibiotic Sales Market Share by Region in 2020
Figure 22. Global VRE and MRSA Antibiotic Revenue Market Share by Region (2016-2021)
Figure 23. Global VRE and MRSA Antibiotic Revenue Market Share by Region in 2020
Figure 24. U.S. VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Canada VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Germany VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. France VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. U.K. VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Italy VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Russia VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. China VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Japan VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. South Korea VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. India VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Australia VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Taiwan VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Indonesia VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Thailand VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Malaysia VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Philippines VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Vietnam VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Mexico VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Brazil VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Argentina VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Turkey VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Saudi Arabia VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. UAE VRE and MRSA Antibiotic Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Sales Market Share of VRE and MRSA Antibiotic by Type (2016-2021)
Figure 49. Sales Market Share of VRE and MRSA Antibiotic by Application (2016-2021)
Figure 50. Sales Market Share of VRE and MRSA Antibiotic by Application in 2020
Figure 51. Revenue Share of VRE and MRSA Antibiotic by Application (2016-2021)
Figure 52. Revenue Share of VRE and MRSA Antibiotic by Application in 2020
Figure 53. Manufacturing Cost Structure of VRE and MRSA Antibiotic
Figure 54. Manufacturing Process Analysis of VRE and MRSA Antibiotic
Figure 55. VRE and MRSA Antibiotic Industrial Chain Analysis
Figure 56. Channels of Distribution
Figure 57. Distributors Profiles
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
